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Abstract
Background Lisdexamfetamine dimesylate (LDX)
demonstrated efficacy in terms of reduced binge eating
days per week in adults with binge eating disorder (BED)
in two randomized clinical trials (RCTs).
Objective The objective of this study was to evaluate the
cost effectiveness of LDX versus no pharmacotherapy
(NPT) in adults with BED from a USA healthcare payer’s
perspective.
Study Design and Methods A decision-analytic Markov
cohort model was developed using 1-week cycles and a
52-week time horizon. Markov health states were defined
based upon the Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition criteria of BED. Model
parameter estimates were obtained from RCTs, a survey,
and literature. The primary outcome was incremental cost-
effectiveness ratio (ICER). The analysis assumed a
12-week course of treatment, based upon RCTs’ treatment
duration. One-way deterministic and probabilistic
sensitivity analyses were conducted to assess the robust-
ness of the results.
Results Patients on LDX therapy gained 0.006 quality-ad-
justed life years (QALY) compared to patients on the NPT
arm, while the average total cost was US$175 higher for LDX
therapy. The estimated ICER for LDX compared with NPT
was US$27,618 per QALY, which was shown to be cost
effective given a willingness-to-pay threshold of US$50,000.
Conclusions Treatment of BED with LDX showed
increase in QALYs at an acceptable cost and is considered
to be cost effective at the commonly used willingness-to-
pay threshold in the USA. Based on the available evidence,
the current model focused on short-term benefits only.
There is a need to generate additional scientific evidence
supporting long-term benefits of LDX therapy for BED.
Key points for Decision Makers
Binge eating disorder has a significant, under-served
patient population due to the absence of satisfactory
medical treatments.
Lisdexamfetamine dimesylate is a novel
pharmacotherapy that was recently approved by the
United States Food and Drug Administration for the
treatment of binge eating disorder.
These results show that lisdexamfetamine dimesylate
generates improvement in quality-adjusted life years
at an acceptable cost compared with no
pharmacotherapy.
Results suggest that lisdexamfetamine dimesylate is
a cost-effective treatment for binge eating disorder in
the USA.
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1 Introduction
Binge eating disorder (BED) is a chronic psychiatric dis-
order, characterized by recurrent episodes of compulsive
overeating (binge eating episodes) during which patients
consume larger amounts of food than normal, experience
the lack of control and which are not followed by com-
pensatory behaviors (e.g. self-induced vomiting, diuretic or
diet pills abuse, or intense exercising) [1]. Binge eating is
often rooted in poor body image, use of food to deal with
stress, low self-esteem and dysfunctional thoughts [1].
BED appears to affect a broader spectrum of the population
than anorexia nervosa and bulimia nervosa; the lifetime
prevalence of BED is about 1–2 % [2–6]. With the asso-
ciation of BED and obesity, this disorder becomes a clin-
ically significant disorder that presents both medical and
psychiatric issues that impair the health-related quality of
life (HRQoL) and increase healthcare utilization [2, 7].
BED has a large, under-served patient population due to
the absence of satisfactory medical treatments. This is also
supported by the fact that currently only a minority of
patients receive a specific treatment for BED [4, 7, 8].
Therapies are intended to treat and control the symptoms of
BED, such as binge eating, overweight, and the disorder-
specific psychopathology [9]. Treatment options of BED
include pharmacological and non-pharmacological thera-
pies applied alone or in combination. Studies support the
effectiveness of non-pharmacological interventions (i.e.
cognitive behavioral therapy, interpersonal psychotherapy,
dialectical behavior therapy, and behavioral weight-loss
therapy) in the treatment of BED [10]. Nevertheless, non-
pharmacological interventions have demonstrated only a
minimal impact on weight control in the long term [10],
and may not be suitable for people who have more complex
mental health needs, or learning difficulties. While some
limited scientific evidence suggests that selective serotonin
reuptake inhibitors (e.g. fluoxetine) [11–13], serotonin–
norepinephrine reuptake inhibitors (e.g. duloxetine) [14],
and antiepileptic drugs (e.g. topiramate) [15, 16] have an
advantage over placebo for achieving reduced binge eating
frequency and decreased body weight, none of these drugs
is approved for the treatment of BED [17].
Lisdexamfetamine dimesylate (LDX, Vyvanse) 50 and
70 mg is a novel pharmacotherapy that was recently
approved by the United States Food and Drug Adminis-
tration (US FDA) for the treatment of adults with BED.
LDX demonstrated efficacy versus placebo in decreasing
binge eating days per week from baseline in two random-
ized, placebo-controlled, parallel-group, multicenter stud-
ies, with the same design and methods (i.e. SPD489-343
and SPD489-344) [18]. LDX also showed improvement in
binge eating-related secondary endpoints (e.g. binge eating
episodes per week, the global impressions of BED
improvement, 4-week cessation from binge eating, change
in body weight, obsessive/compulsive binge eating symp-
toms, and triglycerides) [18]. LDX may be a first-line drug
therapy option in BED with or without psychotherapy, as
determined by physicians.
Under budgetary constraints, cost-effectiveness analyses
have increasingly been used as a tool to select health
interventions for public financing. Cost-effectiveness
analysis permits comparing different treatment options
upon these health benefits and economic value [19]. The
objective of this study was to assess the cost effectiveness
of LDX compared with no pharmacotherapy (NPT, pla-
cebo) for the treatment of adult BED patients from a US
healthcare payer perspective.
2 Methods
A decision-analytic Markov cohort model (Microsoft Excel
2010)was designed using a 52-week time horizon to estimate
the cost effectiveness of LDX compared with NPT. NPTwas
represented by placebo in terms of effect. The model was
designed from the healthcare payer perspective in the USA,
thus only health outcomes [i.e. quality-adjusted life years
(QALYs)] and direct medical costs were considered in the
analysis. Because of the 52-week time horizon, no dis-
counting was performed. The choice of this relatively short
time horizon can be justified by the lack of long-term data
(LDX pivotal trials in BED were 12-week long [18]) that
could be used to inform the economic model in terms of the
long-term benefits of LDX therapy in BED.
The Markov model consisted of seven mutually exclu-
sive health states as presented in Fig. 1 with the duration of
each cycle being 1 week. Health states were defined in
accordance with Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition (DSM-5) criteria [1]. The
1-week cycle length was chosen because this time period
was appropriate to determine DSM-5 binge eating behavior
severity states [1]. Mortality was not included in this
analysis as the time horizon of the model was 52 weeks
and there were no data available on the effect of LDX on
mortality in BED patients.
The model was used to consider a cohort of 1000 adult
BED patients. Gender ratio applied in the analysis was
based on US-based population estimates [20] and gender-
specific 12-month DSM-5 BED prevalence rates [Kantar
Health. VALIDATE study: binge eating disorder final
report. 2014. Data on file at Shire; Cossrow N, Russo LJ,
Ming EE, Witt EA, Victor TW, Wadden TA. Estimating
the prevalence of binge eating disorder in a community
sample comparing DSM-IV-TR and DSM-5 criteria. Poster
presented at: American Psychiatric Association 167th
306 T. A´gh et al.
Annual Meeting. May 3–7, 2014. New York, NY]. Binge
eating behavior severity characteristics of the patient
population entering the model were assumed to match
those observed in the Validate Attitudes and Lifestyle
Issues in Depression ADHD and Troubles with Eating
(VALIDATE) survey [Kantar Health. VALIDATE study:
binge eating disorder final report. 2014. Data on file at
Shire]. VALIDATE was a self-administered, internet
health-based survey completed by US adults, which used a
sample source including respondents of the Kantar Health
2012 and 2013 US National Health and Wellness Survey.
The survey included questions related to demographics,
general health, healthcare utilization, and diagnosed psy-
chiatric disorders, as well as questions designed to assess
the DSM-5 criteria for BED. A total of 22,397 respondents
completed the VALIDATE survey [Kantar Health. VALI-
DATE study: binge eating disorder final report. 2014. Data
on file at Shire; Cossrow N, Russo LJ, Ming EE, Witt EA,
Victor TW, Wadden TA. Estimating the prevalence of
binge eating disorder in a community sample comparing
DSM-IV-TR and DSM-5 criteria. Poster presented at:
American Psychiatric Association 167th Annual Meeting.
May 3–7, 2014. New York, NY]. Characteristics of popu-
lation entering the model are shown in Table 1.
The choice of using NPT (placebo) as comparator is
supported by the facts that (1) no comparative data with
other intervention exist and there is no ongoing LDX
clinical trial with active comparator, (2) no other drug
therapy is approved for the treatment of BED in the USA,
and (3) currently only a minority of BED patients receive
pharmacological and/or non-pharmacological treatment
specifically for their eating disorder [2].
There are no real-world data on the expected duration
of LDX therapy in BED. In the analysis, the treatment
length was set to 12 weeks with steady relapse after
Fig. 1 Structure and patient pathways of the cost-effectiveness
model. Non-symptomatic BED: after full criteria for BED were
previously met, but binge eating occurs less than once per week for at
least 4 weeks; BED with sub-threshold binge eating behavior week 1,
week 2, and week 3: after full criteria for BED were previously met
and less than one binge eating episode for 1, 2, or 3 week(s); BED
with mild binge eating behavior: after full criteria for BED were
previously met and 1 to 3 binge eating episode(s) per week; BED with
moderate binge eating behavior: after full criteria for BED were
previously met and more than three to seven binge eating episodes per
week; BED with severe and extreme binge eating behavior: after full
criteria for BED were previously met and more than seven binge
eating episodes per week. BE binge eating, BED binge eating disorder
Table 1 Patient population entering the model
Parameters Values (%)
Femalea 62.93
Binge eating behavior severity distributionb
BED with mild binge eating behavior 51.45
BED with moderate binge eating behavior 47.09
BED with severe and extreme binge eating behavior 1.46
BED binge eating disorder
a Data source: US based population estimates (projected for 2015):
US Census Bureau [20], gender-specific 12-month BED prevalence
rates (DSM-5, projected for the US population): VALIDATE survey
[Kantar Health. VALIDATE study: binge eating disorder final report.
2014. Data on file at Shire; Cossrow N, Russo LJ, Ming EE, Witt EA,
Victor TW, Wadden TA. Estimating the prevalence of binge eating
disorder in a community sample comparing DSM-IV-TR and DSM-5
criteria. Poster presented at: American Psychiatric Association 167th
Annual Meeting. May 3–7, 2014. New York, NY]
b Data source: VALIDATE survey [Kantar Health. VALIDATE
study: binge eating disorder final report. 2014. Data on file at Shire]
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treatment was completed, which was chosen for the fol-
lowing reasons: (1) in the LDX pivotal clinical trials the
treatment period was 12 weeks long [18]; and (2) when
conducting this analysis no efficacy data for long-term
treatment existed and there were no data on recurrence
and remission of BED after the discontinuation of LDX
therapy.
Transition probabilities between Markov health states
were calculated based on individual binge eating behavior
severity data (i.e. number of binge eating episodes in the
last week) from the pivotal clinical trials [18] for both LDX
and NPT arms. Online Resource 1 depicts the transition
probability matrices for LDX and NPT arms. The model
assumed steady relapse after LDX treatment was com-
pleted, thus after the 12th cycle transition probabilities
were equal in both arms. Discontinuation due to adverse
events (AEs) on the LDX arm was considered in the
analysis.
Utility values were estimated based on the EQ-5D-5L
individual patient level data of the pivotal clinical trials
[18] by applying the EQ-5D-5L value set developed by
EuroQol Group, using US population norms (Table 2).
The model considered two types of costs: drug costs and
medical costs (medical costs included resource utilization
costs and costs of adverse events). The wholesale acqui-
sition cost of LDX was US$6.63 per pill for the 50 and
70 mg strengths. Healthcare utilization data were derived
from the VALIDATE study [Kantar Health. VALIDATE
study: binge eating disorder final report. 2014. Data on file
at Shire]. Healthcare utilization could be calculated for the
following two health states: (1) non-symptomatic BED (as
described previously in Fig. 1), and (2) symptomatic BED
(all patients who do not meet the criteria of non-symp-
tomatic BED health state; i.e. BED with sub-threshold
binge eating behavior week 1–3, BED with mild binge
eating behavior, BED with moderate binge eating behavior,
and BED with severe and extreme binge eating behavior
Markov health states). Health service unit costs were
derived from the 2012 Medical Expenditure Panel Survey
(MEPS) [21]. All cost data applied in the model were
inflated to the year of 2013 using US-specific gross
domestic product deflator [22]. For weekly healthcare
utilization data and health service unit costs, please see
Table 3.
Treatment-emergent AEs related to LDX therapy
occurring in more than 5 % of subjects in the pivotal
clinical trials [18] were considered in the analysis, i.e. dry
mouth, insomnia, headache, nausea and decreased appetite
(weekly incidence rates of AEs were 0.64, 0.29, 0.13, 0.18,
and 0.13 %, respectively). Costs of AEs were assumed to
be resolved during the cycle in which the AE took place.
Costs of AEs per week associated with LDX therapy were
calculated by multiplying the weekly incidence of AEs
with cost of family doctor visit (US$154.62) [22]. Dis-
utilities linked to AEs were considered during the utility
estimation of health states [18]. Patients who discontinued
therapy were assumed to generate the mean utility and
mean cost per week of patients on NPT arm (0.0175 QALY
per week, US$132.05 per week).
By systematically changing the base-case estimates [i.e.
each variable by ±10 % (utility values were maximized at
1.00, thus utility of non-symptomatic BED health state
could be increased only by 5.35 %; to be able to compare
the effect of uncertainty related to utility variables
±5.35 % were applied for all utility variables)], a series of
one-way deterministic sensitivity analyses (DSA) was
programmed and run through the model to find the most
sensitive parameters [23]. Probabilistic sensitivity analysis
(PSA) was also performed to account for the simultaneous
effect of uncertainty relating to model parameter values;
10,000 model iterations were run by using Monte Carlo
simulation. In the PSA, transition probabilities, utilities and
AE incidence rates were sampled from beta distributions,
and healthcare utilization frequencies and costs were
sampled from gamma distributions. Parameters for sam-
pling distributions were derived from point estimates and
standard errors for each variable [24].
Quality-control procedures were performed by a mod-
eler not involved in the model development according to a
pre-specified test plan and included both programming
validation and the verification of all input data with their
original sources. In addition, a series of diagnostic tests
were conducted to confirm that the model was correctly
applying all formulas.
Table 2 Utility values per
Markov health states
Markov health states Utility values
Non-symptomatic BED 0.949
BED with sub-threshold binge eating behavior week 1–3 0.939
BED with mild binge eating behavior 0.909
BED with moderate binge eating behavior 0.886
BED with severe and extreme binge eating behavior 0.877
BED binge eating disorder
Data source: SPD489-343 and SPD489-344 clinical trials [18]
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3 Results
Average direct medical costs per patient incurred over a
52-week time period were estimated at US$6867 for NPT
and US$7042 for LDX, resulting in an incremental total
cost of US$175 for LDX compared with NPT. The esti-
mated QALYs during the 52-week time period was 0.911
and 0.917 for NPT and LDX, respectively. This resulted in
an incremental QALY of 0.006, comparing NPT with
LDX. Thus, the incremental cost-effectiveness ratio
(ICER) with the use of LDX compared to NPT was
US$27,618 per QALY (Table 4).
DSA demonstrated that the model was most sensitive to
the utility of ‘non-symptomatic BED’ health state but
responsive to changes in other model parameters. The
tornado diagram in Fig. 2 highlights the 25 most sensitive
variables on the ICER when base-case estimates were
changed by ±10 % (except utility variables which could be
changed only by ±5.35 %, as utility values were maxi-
mized at 1.00).
PSA was undertaken that ran 10,000 model iterations,
comparing LDX with NPT. The performed PSA demon-
strated that LDX had an 82 % chance of being cost
effective in the treatment of BED at a willingness-to-pay
threshold of US$50,000 per QALY [25] (Fig. 3).
4 Discussion
This is the first study to examine the cost effectiveness of
LDX compared to NPT (placebo) for the treatment of
adults with BED in the USA. Results of this Markov model
showed that BED patients treated with LDX for 12 weeks
had better clinical outcomes [18] at slightly increased
costs. The overall ICER was US$27,618 per QALY sug-
gesting that LDX may be a cost-effective option compared
with NPT in adult patients with BED considering a will-
ingness to pay threshold of US$50,000. These findings can
support healthcare payers regarding the efficient allocation
of health resources, as cost-effective interventions are
highly desirable in improving healthcare system efficiency.
Based on the results of the conducted DSA, the most
sensitive input parameter was the utility value of ‘non-
symptomatic BED’ health state; the influence of other
model parameters was less marked. A cost-effectiveness
acceptability curve was also calculated, showing the
probability of cost effectiveness of LDX given varying
willingness to pay for a QALY. At the commonly used
willingness to pay threshold (US$50,000) in the USA [26],
compared with NPT, LDX had an 82 % chance of being
cost effective in BED.
LDX is a novel treatment for BED and when conducting
this analysis no long-term efficacy data to estimate its
potential long-term benefits in BED, including long-term
reduction in body weight and the health consequences of
weight reduction (e.g. decrease in the prevalence and the
severity of diabetes, hypertension, hypercholesterolemia,
heart failure, ischemic heart disease) were available, that
may affect the cost effectiveness of LDX in the long run.
Evidence suggests that the budget impact of introducing
LDX for the treatment of BED would be modest in the
USA [26]. In a budget-impact analysis, the total direct
budgetary cost of treating BED within the adult US pop-
ulation without LDX was estimated to be US$241,699,596
Table 3 Weekly healthcare utilization data and health service unit costs
Non-symptomatic BED
Mean number of visits per weekd
Symptomatic BED
Mean number of visits per weekd
Cost per unitb
2013 USDe
General internist/family doctor visit 0.0591 0.0921 $163.41
Psychiatrist visit 0.0061 0.0238 $157.46
Psychologist visit 0.0049 0.0171 $143.64
Psychotherapist visit 0.0117 0.0330 $143.64
Nurse practitioner visit 0.0126 0.0247 $153.84
Gynecologist visit (only for women) 0.0209 0.0291 $234.50
Emergency room visit 0.0054 0.0129 $517.82
Hospitalizationa 0.0035 0.0083 $12,959.98c
BED binge eating disorder, 2013 USD United States dollar, year 2013
a International Classification of Diseases—Version 9, 307
b Median cost
c Mean (standard deviation) number of nights per hospital event: 3.00 (1.73)
d Data source: VALIDATE survey [Kantar Health. VALIDATE study: binge eating disorder final report. 2014. Data on file at Shire]
e Data source: Medical Expenditure Panel Survey 2012 [22]
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over one year [26]. If LDX were to treat 17.5 % of patients
diagnosed with BED, then the expected total annual budget
would increase by US$1,069,080 in the USA, which would
be primarily due to the drug cost of LDX, as there would be
expected healthcare utilization costs savings of
US$2,257,096 [26].
The findings of this cost-effectiveness analysis should
be considered in the light of the following limitations:
• Although, Markov health states were constructed in
accordance with the DSM-5 criteria, health states were
solely based on the frequency of binge eating episodes.
Other disease severity symptoms such as psychological
distress or obsessive/compulsive behavior were not
taken into account.
• Patients treated with LDX were assumed to take the
drug for 12 weeks in accordance with the two phase III
pivotal clinical trials; at this time long-term efficacy
data were not available to establish treatment duration.
• Steady relapse was assumed after LDX treatment was
completed; no data exist on recurrence and remission of
BED after the discontinuation of LDX therapy.
• It is worth noting that cost of hospitalization was not
specific to BED, but to International Classification of
Diseases—Version 9 (ICD-9) 307 ‘special symptoms or
syndromes not elsewhere classified’. The reason for this
was that BED is not recognized in ICD, which is the
official system of assigning codes to diagnoses in the






Total cost $7,041.92 $6,866.52 $175.41
QALY 0.9171 0.9108 0.0064
ICER $27,617.56
Average costs per patient
Drug $541.82 $0.00 $541.82







Hospitalization $4,659.70 $4,956.31 -$296.61
Adverse events $24.89 $0.00 $24.89
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
a Costs of general internist/family doctor visit and nurse practitioner visit
b Costs of gynecologist visit (only for women), psychiatrist visit, psychologist visit, and psychotherapist
visit
Fig. 2 Tornado diagram presenting the impact of changing the 25
most sensitive variables on the ICER. BE binge eating, BED binge
eating disorder, ICER incremental cost-effectiveness ratio, LDX
Lisdexamfetamine dimesylate, NPT no pharmacotherapy, trans prob
transition probability
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unspecified’ (EDNOS); however, cost data for 4-digit
ICD codes are not available in Medical Expenditure
Panel Survey (MEPS).
• The present study might be cautiously generalized to
real-world setting, since effectiveness parameters, such
as medication adherence and discontinuation rates, can
be considerably different. We chose not to account with
medication adherence in this analysis as the majority of
subjects in the pivotal clinical trials were adherent to
LDX [18] and no real-world data on adherence to LDX
in BED exist.
5 Conclusions
Treatment of BED with LDX showed an increase in
QALYs at an acceptable cost and is considered cost
effective at the commonly used willingness-to-pay thresh-
old (US$50,000) in the USA. Based on the available evi-
dence the current model focused on short-term benefits
only; however, additional scientific evidence supporting
long-term benefits may further validate the health eco-
nomic results.
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